

Patient Name _____ DOB _____ Weight _____ Male Female
 Street Address _____ Apt # _____ City _____ State _____ Zip _____
 Daytime Tel _____ Evening Tel _____ Cell _____ Email _____ Date Needed _____
 Ship to Patient at Home Work **OR** Patient will pick up at Physician Office Pharmacy Fibrosure Fibrotest Results _____
 ICD-10 Diagnosis _____ Biospsy Yes No Results _____ Previously treated Yes No If yes, what drugs _____
 HCV MEDICAL CRITERIA Genotype _____ HCV-Viral Load _____ (IU) Date of Labs _____ ALT _____ AST _____ Hgb _____

Insured's Name _____ Relation to Patient _____ Eligible for Medicare Yes No If yes, Medicare# _____
 Prescription Card Yes No If Yes, Carrier _____ Tel _____ Fax _____ Policy/Group# _____
 Bin# _____ Pcn# _____ RXID# _____ RX Group# _____

Prescriber's Name _____ Office Contact _____
 Street Address _____ Suite # _____ City _____ State _____ Zip _____
 Tel _____ Fax _____ Email _____
 License# _____ NPI# _____ UPIN# _____ DEA# _____

PRESCRIPTION

PLEASE ATTACH COPIES OF PATIENT'S INSURANCE CARDS

VIEKIRA QTY 28 Day Supply Refill x _____
 Ombitasvir/Paritaprevir/Ritonavir 12.5mg/75 mg/50 mg tabs (pink) and Dasabuvir 250 mg tab (beige)
 Directions: Take 2 pink tablets PO once daily (AM) with food and one beige tablet PO twice daily (AM and PM) with food

Treatment Regimen and Duration by Patient Population		
Patient Population	Treatment*	Duration
Genotype 1a, with-out cirrhosis	VIEKIRA PAK + ribavirin	12 weeks
Genotype 1a, with cirrhosis	VIEKIRA PAK + ribavirin	24 weeks**
Genotype 1b, with-out cirrhosis	VIEKIRA PAK	12 weeks
Genotype 1b, with cirrhosis	VIEKIRA PAK + ribavirin	12 weeks

*Note: Follow the genotype 1a dosing recommendations in patients with an unknown genotype 1 subtype or with mixed genotype 1 infection.
 **VIEKIRA PAK administered with ribavirin for 12 weeks may be considered for some patients based on prior treatment history

OLYSIO (Simeprevir) 150mg cap Qty: _____ Refill: _____
 Directions: Take 1 capsule by mouth with food daily for 12 weeks with peginterferon and ribavirin

TECHNIVIE Genotype 4 ONLY
 paritaprevir/ritonavir (75/50 mg) and ombitasvir (12.5 mg)
 SIG: two tablets QAM with a meal and along with RIBAVIRIN
 Qty: _____ Refill: _____
 RIBAVIRIN 200mg tablet SIG: take 1 tablet twice a day
 Qty: _____ Refill: _____

RIBAPAK **MODARIBA**
 Ribapak 600mg PO Daily; 200mg QAM, 400mg QPM
 Ribapak 800mg PO Daily; 400mg QAM, 400mg QPM
 Ribapak 1000mg PO Daily; 600mg QAM, 400mg QPM
 Ribapak 1200mg PO Daily; 600mg QAM, 600mg QPM
 Ribavirin 200mg Sig _____
 QTY _____ Refills _____

HARVONI Ledipasvir 90mg / Sofosbuvir 400mg
 12 weeks treatment-naïve with or without cirrhosis
 12 weeks treatment-experienced without cirrhosis
 24 weeks treatment-experienced with cirrhosis
 8 weeks treatment (can be considered) in naïve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL
 SIG: Take 1 tablet by mouth daily QTY _____ Refill x _____

DAKLINZA (daclatasvir) Genotype 3 only
 30 mg / 400 mg SOVALDI Qty: 28 Refills: _____
 60 mg / 400 mg SOVALDI Qty: 28 Refills: _____
 SIG: take 1 tablet each daily Total daily dose: _____

PEGASYS QTY: 1 month 3 month Refill x _____
 ProClick **135mcg Autoinjector** (NDC 004-0365-30) Inject SQ weekly
 ProClick **180mcg Autoinjector** (NDC 004-0365-30) Inject SQ weekly
 Pre-Filled Syringe 180mcg/0.5ml (NDC 004-0357-30) Inject SQ weekly
 Other _____

SOVALDI (Sofosbuvir) 400mg tablet
 Take 1 tablet by mouth daily for:
 12 weeks w/ Ribapak and peginterferon (Geno 1 or 4)
 24 weeks with Ribapak (Genotype 1 or 4)
 12 weeks with Ribapak (Genotype 2)
 24 weeks with Ribapak (Genotype 3)
 QTY _____ Refills _____

OTHER _____ Strength _____
 Qty _____ Refill x _____ Months
 SIG: _____

By signing this form and utilizing our services, you are authorizing Padek Healthcare and it's employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

Prescriber's Signature (signature required. NO STAMPS) _____ **Date** _____

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.